Filter By Category
Archives
Share on -
DANVILOSTOMIG
Generic Name: DANVILOSTOMIG
ABSTRACT -
Danvilostomig is an investigational bispecific immune-checkpoint antibody designed to engage PD-1 and CTLA-4 pathways. It is a biologic, so a single small-molecule formula and ordinary 2D bond-line structure are not applicable.
DOSAGE -
- No routine clinical dosage is established for general use.
- Infusion dose, schedule, premedication, and monitoring must follow clinical-trial protocol.
- Use only in centers able to manage immune-mediated toxicities.
SIDE EEFECTS -
- Infusion reactions, fatigue, fever, rash, pruritus, diarrhea, nausea, or arthralgia may occur.
- Immune-mediated colitis, hepatitis, pneumonitis, endocrinopathy, nephritis, and severe skin reactions are possible.
- Laboratory abnormalities such as cytopenias or elevated transaminases may occur.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- Other immunotherapies may increase immune-related adverse reactions.
- Corticosteroids or immunosuppressants may be needed for toxicity and may alter antitumor activity.
- Live vaccines require specialist guidance.
PREAUTONS–
- Monitor for immune-mediated toxicity throughout treatment and after discontinuation.
- Use caution in autoimmune disease, transplant recipients, severe infection, or organ dysfunction.
- Pregnancy and lactation require specialist review.
WARNINGS –
- Serious or fatal immune-mediated events can occur with checkpoint-pathway biologics.
- Urgent evaluation is needed for shortness of breath, severe diarrhea, jaundice, neurologic symptoms, or anaphylaxis.
- Keep out of reach of children.
Share on -
. Developed by